<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02795325</url>
  </required_header>
  <id_info>
    <org_study_id>DCR-PH1-101</org_study_id>
    <nct_id>NCT02795325</nct_id>
  </id_info>
  <brief_title>A Study of DCR-PH1 in Patients With Primary Hyperoxaluria Type 1 (PH1)</brief_title>
  <official_title>A Phase 1 Study of DCR-PH1 in Patients With Primary Hyperoxaluria Type 1 (PH1)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dicerna Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dicerna Pharmaceuticals, Inc.</source>
  <brief_summary>
    <textblock>
      A phase 1 study of DCR-PH1 in patients with primary hyperoxaluria type 1 (PH1) to determine
      the safety, tolerability, pharmacokinetic (PK) and pharmacodynamics (PD) effects of DCR-PH1
      administered via-intravenous infusion (IV)
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date type="Actual">May 13, 2016</start_date>
  <completion_date type="Actual">October 14, 2016</completion_date>
  <primary_completion_date type="Actual">October 14, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The safety of DCR-PH1 evaluated by the proportion of subjects that experience adverse events (AEs)</measure>
    <time_frame>Through Day 29</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Profile of pharmacokinetics (PK) of DCR-PH1 - Cmax</measure>
    <time_frame>Through Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Profile of pharmacokinetics (PK) of DCR-PH1 - tmax</measure>
    <time_frame>Through Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Profile of pharmacokinetics (PK) of DCR-PH1 - AUC</measure>
    <time_frame>Through Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Profile of pharmacokinetics (PK) of DCR-PH1 - t½</measure>
    <time_frame>Through Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of DCR-PH1 on plasma glycolate levels</measure>
    <time_frame>Through Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of DCR-PH1 on urine glycolate levels</measure>
    <time_frame>Through Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of DCR-PH1 on plasma oxalate levels</measure>
    <time_frame>Through Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of DCR-PH1 on urine oxalate levels</measure>
    <time_frame>Through Day 29</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Primary Hyperoxaluria Type 1</condition>
  <arm_group>
    <arm_group_label>PH Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DCR-PHXC</intervention_name>
    <description>IV infusion of DCR-PH1</description>
    <arm_group_label>PH Patients</arm_group_label>
    <arm_group_label>Healthy Volunteers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Healthy Volunteers</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, at least 12 years of age

          -  Diagnosis of PH1, confirmed by genotyping

          -  24-hour urine oxalate excretion as defined in the protocol

          -  eGFR ≥ 40 mL/min normalized to 1.73 m2 BSA

          -  Written informed consent for adults (≥18 years old, or per local regulatory
             requirement); written informed assent for adolescents (12 to &lt;18 years old, or per
             local regulatory requirement)

        Exclusion Criteria:

          -  Prior renal and/or hepatic transplantation

          -  Participation in any clinical study involving administration of any investigational
             drug within the 30 days before enrollment

          -  Pregnancy or lactation at the time of screening or enrollment

          -  Women of child-bearing potential must have a negative pregnancy test, cannot be
             breastfeeding and must be willing to use contraception

          -  Patients with a known history of human immunodeficiency virus (HIV) or active
             infection with hepatitis B virus or hepatitis C virus

          -  Moderate to severe liver impairment

          -  Liver function test abnormalities: alanine transaminases (ALT) and/or aspartate
             transaminases (AST) &gt; 2 times upper limit of normal (ULN)

          -  History of severe reaction to a liposomal product or a known hypersensitivity to lipid
             products.

          -  Unable to collect required study samples or follow study procedures

          -  No clinically significant health concerns
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://www.dicerna.com</url>
  </link>
  <link>
    <url>http://www.rarekidneystones.org</url>
  </link>
  <link>
    <url>http://www.ohf.org</url>
  </link>
  <link>
    <url>http://www.nord.org</url>
  </link>
  <reference>
    <citation>Martin-Higueras C, Luis-Lima S, Salido E. Glycolate Oxidase Is a Safe and Efficient Target for Substrate Reduction Therapy in a Mouse Model of Primary Hyperoxaluria Type I. Mol Ther. 2016 Apr;24(4):719-25. doi: 10.1038/mt.2015.224. Epub 2015 Dec 22.</citation>
    <PMID>26689264</PMID>
  </reference>
  <reference>
    <citation>Milliner DS. siRNA Therapeutics for Primary Hyperoxaluria: A Beginning. Mol Ther. 2016 Apr;24(4):666-7. doi: 10.1038/mt.2016.50.</citation>
    <PMID>27081720</PMID>
  </reference>
  <reference>
    <citation>Dutta C, Avitahl-Curtis N, Pursell N, Larsson Cohen M, Holmes B, Diwanji R, Zhou W, Apponi L, Koser M, Ying B, Chen D, Shui X, Saxena U, Cyr WA, Shah A, Nazef N, Wang W, Abrams M, Dudek H, Salido E, Brown BD, Lai C. Inhibition of Glycolate Oxidase With Dicer-substrate siRNA Reduces Calcium Oxalate Deposition in a Mouse Model of Primary Hyperoxaluria Type 1. Mol Ther. 2016 Apr;24(4):770-8. doi: 10.1038/mt.2016.4. Epub 2016 Jan 13.</citation>
    <PMID>26758691</PMID>
  </reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 18, 2016</study_first_submitted>
  <study_first_submitted_qc>June 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2016</study_first_posted>
  <last_update_submitted>December 13, 2017</last_update_submitted>
  <last_update_submitted_qc>December 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Primary Hyperoxaluria Type 1</keyword>
  <keyword>PH1</keyword>
  <keyword>Calcium Oxalate Stones</keyword>
  <keyword>Kidney Stones</keyword>
  <keyword>Liver Enzyme Deficiency</keyword>
  <keyword>Genetic Diseases</keyword>
  <keyword>Inborn Kidney Diseases</keyword>
  <keyword>Metabolic Diseases</keyword>
  <keyword>Inborn Errors</keyword>
  <keyword>Urological Diseases</keyword>
  <keyword>Carbohydrate Metabolism</keyword>
  <keyword>Hyperoxaluria</keyword>
  <keyword>AGT</keyword>
  <keyword>RNAi</keyword>
  <keyword>siRNA</keyword>
  <keyword>DCR-PH1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperoxaluria, Primary</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

